The miRNA pathway in neurological and skeletal muscle disease: implications for pathogenesis and therapy

被引:21
|
作者
Sibley, Christopher R. [1 ]
Wood, Matthew J. A. [1 ]
机构
[1] Univ Oxford, Dept Physiol Anat & Genet, Oxford OX1 3QX, England
来源
JOURNAL OF MOLECULAR MEDICINE-JMM | 2011年 / 89卷 / 11期
基金
英国惠康基金;
关键词
RNAi; miRNA; Neurodegeneration; Myopathy; Muscular dystrophy; SERUM RESPONSE FACTOR; PROTEIN-DEFICIENT MICE; CENTRAL-NERVOUS-SYSTEM; PEPTIDE NUCLEIC-ACIDS; NF-KAPPA-B; ALZHEIMERS-DISEASE; IN-VIVO; MICRORNA EXPRESSION; HUNTINGTONS-DISEASE; MESSENGER-RNAS;
D O I
10.1007/s00109-011-0781-z
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
RNA interference (RNAi) represents a powerful post-transcriptional gene silencing network which fine-tunes gene expression in all eukaryotic cells. The endogenous triggers of RNAi, microRNAs (miRNAs), are proposed to regulate expression of up to a third of all protein-coding genes, and have been shown to have critical roles in developmental processes including in the central nervous system and skeletal muscle. Further, many have been reported to display differential expression in various disease states. Here we describe present understanding of the biogenesis and function of miRNAs, review current knowledge of miRNA abnormalities in both human neurological and skeletal muscle disease and discuss their potential as novel disease biomarkers. Finally, we highlight the many ways in which the miRNA pathway may be targeted for therapeutic benefit.
引用
收藏
页码:1065 / 1077
页数:13
相关论文
共 50 条